Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical Implementation of Novel Targeted Therapeutics in Advanced Breast Cancer.

Journal of cellular biochemistry - 1 Nov 2016

Chamberlin Mary D, Bernhardt Erica B, Miller Todd W

Abstract excerpt

The majority of advanced breast cancers have genetic alterations that are potentially targetable with drugs. Through initiatives such as The Cancer Genome Atlas (TCGA) and the International Cancer Genome Consortium (ICGC), data can be mined to provide context for next-generation sequencing (NGS) results in the landscape of advanced breast cancer. Therapies for targets other than estrogen receptor alpha (ER) and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Biomarkers, Tumor
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to CDK6 gene

Share to HDAC1 gene

Share to Molecular Targeted Therapy

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 27146558
DOI: 10.1002/jcb.25590
PMCID: PMC6010350

Genes

CDK4
CDK6
HDAC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical Implementation of Novel Targeted Therapeutics in Advanced Breast Cancer.PMID 27146558Read ↗

Breast Cancer: Epidemiology, Molecular Classification, Diagnostics and Evolving Treatment Paradigms.Semantic proximity Read ↗

The Present and Future of Clinical Management in Metastatic Breast CancerSemantic proximity Read ↗

Evaluation of targeted therapies in advanced breast cancer: the need for large-scale molecular screening and transformative clinical trial designsSemantic proximity Read ↗

Unique molecular signatures as a hallmark of patients with metastatic breast cancer: Implications for current treatment paradigmsSemantic proximity Read ↗

Recent Advances in the Treatment of Breast CancerSemantic proximity Read ↗

Emerging Protein Targets in Triple Negative Breast Cancer: Beyond Conventional TherapySemantic proximity Read ↗

Functional genomics for breast cancer drug target discoverySemantic proximity Read ↗

Genetic Signature of Breast Cancer Defines Therapeutic Interventions and Indicates Early Drug Resistance.Semantic proximity Read ↗

The Future of ER+/HER2- Metastatic Breast Cancer Therapy: Beyond PI3K Inhibitors.Semantic proximity Read ↗

Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer.Semantic proximity Read ↗

Recent Insights Into Breast Cancer: Molecular Pathways, Epigenetic Regulation, and Emerging Targeted TherapiesSemantic proximity Read ↗

Deregulated Immune Pathway Associated with Palbociclib Resistance in Preclinical Breast Cancer Models: Integrative Genomics and Transcriptomics.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.